1-3 of 3
Nisha Philipose
Close
Sort by
Journal Articles

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

Clinical Trials & Observations
Eunice S. Wang, Pau Montesinos, Mark D. Minden, Je-Hwan Lee, Michael Heuser, Tomoki Naoe, Wen-Chien Chou, Kamel Laribi, Jordi Esteve, Jessica K. Altman, Violaine Havelange, Anne-Marie Watson, Carlo Gambacorti-Passerini, Elzbieta Patkowska, Shufang Liu, Ruishan Wu, Nisha Philipose, Jason E. Hill, Stanley C. Gill, Elizabeth Shima Rich, Ramon V. Tiu
Journal: Blood
Blood (2022) 140 (17): 1845–1857.
https://doi.org/10.1182/blood.2021014586
Published: 2022
Includes: Supplemental data
Journal Articles

A Phase 1, Dose-Escalation Study of Gilteritinib Combined with Chemotherapy in Patients Aged 6 Months to <21 Years with FLT3 Internal Tandem Duplication-Positive Relapsed or Refractory AML

Philip Connor, Linyi Fan, Stanley Gill, Jason E. Hill, Nisha Philipose, David Delgado, Ramon V. Tiu, Dirk Reinhardt
Journal: Blood
Blood (2021) 138 (Supplement 1): 2315.
https://doi.org/10.1182/blood-2021-147862
Published: 2021
Journal Articles

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Eunice S. Wang, Pau Montesinos, Mark D. Minden, Je-Hwan Lee, Michael Heuser, Tomoki Naoe, Wen-Chien Chou, Kamel Laribi, Jordi Esteve, Jessica K. Altman, Violaine Havelange, Anne-Marie Watson, Elzbieta Patkowska, Shufang Liu, Ruishan Wu, Nisha Philipose, Jason E. Hill, Stanley Gill, Elizabeth Shima Rich, Ramon V. Tiu
Journal: Blood
Blood (2021) 138 (Supplement 1): 700.
https://doi.org/10.1182/blood-2021-145379
Published: 2021